Asthma – Global Drug Forecast and Market Analysis to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$14995
Buy Report Download FREE Resources

Published: December 31, 2020 Report Code: GDHC208PIDR-ST

Select Item

Asthma Market Report Overview

The asthma market size across the 7MM was $9.7 billion in 2019 and will achieve a CAGR of more than 1% during 2019-2029. Asthma is a common chronic lung disease characterized by chronic inflammation and subsequent narrowing of the airways that most often develops during childhood but can occur at any age. It can be persistent or intermittent and varies by severity. The symptoms of asthma are often triggered by factors such as exercise, allergen or irritant exposure, and even viral infections.

Asthma Market Outlook, 2019-2029 ($ Billion)

Asthma Market Outlook, 2019-2029 ($ Billion)

Buy Full Report to Gain More Insights into the Asthma Market Forecast

Download a Free Report Sample

The asthma market research covers the 7MM (the US, France, Germany, Italy, Spain, Japan, and the UK) and provides a forecast model for the asthma market through 2031.

Market Size (2019) $9.7 billion
CAGR (2019 – 2029) >1%
Historical Period 2019-2022
Forecast Period 2023-2029
Key Class of Drugs ·       Monoclonal antibodies

·       Inhaled Corticosteroids (ICS)

·       ICS/LABA Fixed Dose Combinations

·       Leukotriene Inhibitors

·       Long-Acting Muscarinic Antagonists (LAMAs)
Leading Players ·       GlaxoSmithKline

·       Novartis

·       Roche/Genentech

·       GlaxoSmithKline

·       Teva
Enquiry & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Asthma Market Insights

The increasing pressures for cost-effectiveness limit the pricing of new products and in some cases prevent their reimbursement as well, which is negatively impacting the market growth. However, strong brand loyalty and difficulty replacing inhaler devices will soften the impact of generic erosion and will propel the asthma market growth during the forecast period.

Asthma Market – Treatment Insights

  • A diagnosis of asthma is mostly made by a primary care physician (PCP) and the diagnostic criteria for asthma are laid out by the GINA. It is commonly diagnosed based on a patient’s medical history and symptoms, which include recurrent wheezing, shortness of breath, recurrent dyspnea, coughing, and sensitivity to common allergens.
  • Spirometry is the preferred method of lung function testing used to establish airflow limitation when diagnosing asthma. Moreover, the measurement of FEV1 by spirometry in response to bronchodilative therapy facilitates the diagnosis of asthma.
  • Asthma is more difficult to diagnose in several patient groups. Further, diagnosing asthma in children younger than five years of age is complicated by the fact that not all wheezing in children is due to asthma. Therefore, diagnosis in this age group requires continuous review by physicians.

Buy Full Report to Gain More Insights into the Asthma Market Forecast

Download a Free Report Sample

Asthma Market Segmentation by Class of Drugs

In 2021, the leading US drug class asthma market was Monoclonal antibodies.

A few of the key classes of drugs in the US asthma market are Monoclonal antibodies, Inhaled Corticosteroids (ICS), ICS/LABA Fixed Dose Combinations, Leukotriene Inhibitors, and Long-Acting Muscarinic.

Asthma Market Analysis by Class of Drugs in the US, 2019 (%)

Asthma Market Analysis by Class of Drugs in the US, 2019 (%)

Buy Full Report to Get More Insights on the Asthma Classes of Drugs

Download A Free Report Sample

Asthma Market - Competitive Landscape

A few of the leading companies in the asthma market are:

  • GlaxoSmithKline
  • Novartis
  • Roche/Genentech
  • GlaxoSmithKline
  • Teva

GSK was the leading player in 2019 followed by AstraZeneca where both have a variety of successfully marketed products. However, GSK strategically introduced its inhalers to revitalize its respiratory drug portfolio in the face of generic erosion. Since then, GSK’s respiratory portfolio has expanded.

Asthma Market Analysis by Players, 2019 (%)

Asthma Market Analysis by Players, 2019 (%)

Buy Full Report To Get More Insights into the More Asthma Players

Download a Free Report Sample

Segments Covered in the Report

Asthma Class of Drugs Outlook (Value, $ Billion, 2019-2029)

  • Monoclonal antibodies
  • Inhaled Corticosteroids (ICS)
  • ICS/LABA Fixed Dose Combinations
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMAs)

Scope

The report provides:

  • Overview of asthma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

  • Topline asthma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

  • Current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting asthma therapeutics sales in the 7MM.

  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

  • Analysis of the current and future market competition in the global asthma therapeutics market.

  • Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

  • The greatest drivers of growth in the global asthma market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.

  • The main barriers to growth in the asthma market include high genericization of historical drug classes.

  • Late-stage pipeline products in the ICS/LABA/LAMA triple-therapy fixed dose inhalers, CRTH2 antagonists, and ICS/SABA double therapies are emerging as distinct drug classes in the field.

  • The most important unmet needs in the asthma market are improved drug compliance and personalized therapy for the most severe patients.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Track drug sales in the global asthma therapeutics market from 2019-2029.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AstraZeneca
Novartis
Roche/Genentech
GlaxoSmithKline
Teva
Boehringer Ingelheim
Merck
Chiesi
Regeneron/Sanofi
AB Science SA

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Asthma: Executive Summary

2.1 Asthma Market to Experience Conservative Growth Over the Forecast Period

2.2 GlaxoSmithKline and AstraZeneca Lead the Way

2.3 Unmet Needs Remain Surrounding Asthma Diagnosis and Treatment Options for Severe Patients

2.4 Late-Stage Pipeline Addresses Needs for Personalized and Convenient Medications

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification of Disease Severity

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Asthma (2019–2029)

5.5.1 Lifetime Diagnosed Prevalent Cases of Asthma

5.5.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma

5.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma

5.5.4 Lifetime Diagnosed Prevalent Cases of Asthma by Severity

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Treatment Guidelines and Clinical Practice

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

8 Needs and Opportunity Assessment

8.1 Overview

8.2 Accurate Diagnosis

8.3 Personalized Therapies for Severe Asthma

8.4 Increased Patient Compliance

8.5 Lower Cost of Therapy

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Thymic Stromal Lymphopoietin Inhibitors

9.2.2 CRTH2 Antagonist

9.2.3 Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist

9.3 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 AstraZeneca

10.4 Novartis

10.5 Roche/Genentech

10.6 GlaxoSmithKline

10.7 Teva

10.8 Boehringer Ingelheim

10.9 Merck

10.10 Chiesi

10.11 Regeneron/Sanofi

10.12 AB Science SA

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology.

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analysts

12.6.2 Therapy Area Directors

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologists

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Asthma: Key Metrics in the 7MM

Table 2: Classification of Asthma by Severity

Table 3: Risk Factors and Comorbidities for Asthma

Table 4: Treatment Guidelines for Asthma across the 7MM

Table 5: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency

Table 6: Country Profile – US

Table 7: Country Profile – 5EU

Table 8: Country Profile – Japan

Table 9: Leading Treatments for Asthma, 2020

Table 10: AstraZeneca’s Asthma Portfolio Assessment, 2020

Table 11: Novartis’ Asthma Portfolio Assessment, 2020

Table 12: Roche/Genentech Asthma Portfolio Assessment, 2020

Table 13: GlaxoSmithKline’s Asthma Portfolio Assessment, 2020

Table 14: Teva’s Asthma Portfolio Assessment, 2020

Table 15: Boehringer Ingelheim’s Asthma Portfolio Assessment, 2020

Table 16: Merck’s Asthma Portfolio Assessment, 2020

Table 17: Chiesi’s COPD Portfolio Assessment, 2019

Table 18: Regeneron/Sanofi’s Asthma Portfolio Assessment, 2020

Table 19: AB Science Asthma Portfolio Assessment, 2020

Table 20: Asthma Market – Global Drivers and Barriers, 2019–2029

Table 21: Key Events Impacting Sales for Asthma in the US, 2019–2029

Table 22: Asthma Market – Drivers and Barriers in the US, 2019–2029

Table 23: Key Events Impacting Sales for Asthma in the 5EU, 2019–2029

Table 24: Asthma Market – Drivers and Barriers in the 5EU, 2019–2029

Table 25: Key Events Impacting Sales for Asthma in Japan, 2019–2029

Table 26: Asthma Market – Global Drivers and Barriers in Japan, 2019–2029

Table 27: Key Historical and Projected Launch Dates for Asthma

Table 28: Key Historical and Projected Patent Expiry Dates for Asthma

Table 29: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Asthma in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in Asthma During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for Asthma, 2020

Figure 4: Pathophysiology of Asthma

Figure 5: 7MM, Lifetime Diagnosed Prevalence of Asthma (%), Both Sexes, All Ages, 2009–2019

Figure 6: 7MM, Sources Used for Lifetime Diagnosed Prevalence of Asthma (%)

Figure 7: 7MM, Sources Used for Severity of Asthma (%)

Figure 8: Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, Both Sexes, All Ages, N, 2019

Figure 9: Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, Both Sexes, All Ages, N, 2019

Figure 10: Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, All Ages, N, 2019

Figure 11: Lifetime Diagnosed Prevalent Cases of Asthma by Severity, 7MM, Both Sexes, All Ages, N, 2019

Figure 12: GINA 2020 Guidelines for the management of Asthma

Figure 13: Unmet Needs and Opportunities in Asthma

Figure 14: Overview of the Development Pipeline in Asthma

Figure 15: Key Phase II/III Asthma Trials Across the 7MM, 2020

Figure 16: Competitive Assessment of the Late-Stage Pipeline Agents

Figure 17: Analysis of the Company Portfolio Gap in Asthma During the Forecast Period

Figure 18: 7MM, Asthma Sales Forecast by Country, 2019 and 2029

Figure 19: US, Asthma Sales Forecast by Class, 2019 and 2029

Figure 20: 5EU, Asthma Sales Forecast by Class, 2019 and 2029

Figure 21: Japan, Asthma Sales Forecast by Class, 2019 and 2029

Frequently asked questions

Asthma – Global Drug Forecast and Market Analysis to 2029 standard reports
Currency USD
$14,995

Can be used by individual purchaser only

Most Popular
$29,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$44,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Asthma – Global Drug Forecast and Market Analysis to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Respiratory reports
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, August 2026
$2,950 | September 2026
Pharmaceuticals
New
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive…
$3,495 | September 2026
Pharmaceuticals
New
Hodgkin Lymphoma: Epidemiology Report and Forecast
$9,995 | September 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Asthma – Global Drug Forecast and Market Analysis to 2029 in real time.

  • Access a live Asthma – Global Drug Forecast and Market Analysis to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more